Company Encyclopedia
View More
name
Soligenix
SNGX.US
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet’s disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola.
1.946 T
SNGX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking312/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-165.10%E
    • Profit Margin0.00%D
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY-100.00%E
    • Net Profit YoY-57.37%D
    • Total Assets YoY7.80%B
    • Net Assets YoY28.02%A
  • Cash ScoreD
    • Cash Flow Margin0.00%D
    • OCF YoY-100.00%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreB
    • Gearing Ratio32.73%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Soligenix Inc. unveils pipeline progress and rare disease treatment strategies in new corporate presentation

    Soligenix Inc. has released a corporate presentation detailing progress in its rare disease treatment pipeline and public health solutions. Highlights include Phase 2a clinical study success for SGX302 in psoriasis and SGX945 in Behçet’s Disease. The company is advancing vaccine candidates for ricin toxin, Ebola, Marburg, and COVID-19, supported by government funding. Several products are in late-stage clinical studies and regulatory discussions.

    Reuters·
    US
    SNGX
    +5.16%
    Reuters·
    US
    SNGX
    +5.16%

    Soligenix Reaches Interim Enrollment Milestone in Phase 3 HyBryte Trial for CTCL

    Soligenix Inc. has completed patient enrollment for the interim analysis of its Phase 3 HyBryte trial for CTCL, reaching a milestone with 50 out of 80 patients enrolled. The interim analysis is set for Q2 2026, with a current blinded study response rate of 48%, surpassing the initial 25% estimate. Topline results are expected in H2 2026.

    Reuters·
    US
    SNGX
    +5.16%
    Reuters·
    US
    SNGX
    +5.16%

    Soligenix Regains Nasdaq Compliance After Equity Shortfall

    Soligenix Inc. has resolved its compliance issue with Nasdaq, surpassing the minimum stockholders’ equity requirement of $2.5 million by reporting $7.6 million in its latest quarterly report. Nasdaq has confirmed that Soligenix is now in compliance, closing the matter.

    Reuters·
    US
    SNGX
    +5.16%
    Reuters·
    US
    SNGX
    +5.16%

    Soligenix | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    SNGX
    +5.16%
    LB filings·
    US
    SNGX
    +5.16%

    Biopharma firm Soligenix's Q3 net loss widens on increased R&D spends

    Soligenix reported a Q3 net loss of $2.5 million, widening due to increased clinical trial expenses, with no revenue reported for both Q3 2025 and Q3 2024. The company has $10.5 million in cash, ensuring operations through 2026, and is exploring partnerships to advance its pipeline. Analysts maintain a 'buy' rating, with a median 12-month price target of $17.50, reflecting a potential 92.7% increase from its recent closing price of $1.28.

    Reuters·
    US
    SNGX
    +5.16%
    Reuters·
    US
    SNGX
    +5.16%
    © 2025 Longbridge｜Disclaimer